These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15295684)

  • 1. [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome].
    Rosenkranz S; Caglayan E; Diet F; Karasch T; Weihrauch J; Wassermann K; Erdmann E
    Dtsch Med Wochenschr; 2004 Aug; 129(33):1736-40. PubMed ID: 15295684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil.
    Baumhaekel M; Scheffler P; Boehm M
    Microvasc Res; 2005 May; 69(3):178-9. PubMed ID: 15896360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
    Kamata Y; Kamimura T; Iwamoto M; Minota S
    Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
    [No Abstract]   [Full Text] [Related]  

  • 5. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon.
    Rosenkranz S; Diet F; Karasch T; Weihrauch J; Wassermann K; Erdmann E
    Ann Intern Med; 2003 Nov; 139(10):871-3. PubMed ID: 14623635
    [No Abstract]   [Full Text] [Related]  

  • 7. Sildenafil: emerging cardiovascular indications.
    Raja SG; Nayak SH
    Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
    Rondelet B; Kerbaul F; Van Beneden R; Motte S; Fesler P; Hubloue I; Remmelink M; Brimioulle S; Salmon I; Ketelslegers JM; Naeije R
    Circulation; 2004 Oct; 110(15):2220-5. PubMed ID: 15466636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
    Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
    J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil for primary and secondary pulmonary hypertension.
    Watanabe H; Ohashi K; Takeuchi K; Yamashita K; Yokoyama T; Tran QK; Satoh H; Terada H; Ohashi H; Hayashi H
    Clin Pharmacol Ther; 2002 May; 71(5):398-402. PubMed ID: 12011826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase inhibitors in Raynaud's phenomenon.
    Levien TL
    Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
    Bharani A; Mathew V; Sahu A; Lunia B
    Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.
    Urdaneta F; Willert JL; Beaver T; Naik B; Kirby DS; Lobato EB
    Ann Thorac Surg; 2004 Oct; 78(4):1433-7. PubMed ID: 15464509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
    Guazzi M; Tumminello G; Di Marco F; Fiorentini C; Guazzi MD
    J Am Coll Cardiol; 2004 Dec; 44(12):2339-48. PubMed ID: 15607396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy.
    Chaudhari M; Vogel M; Wright C; Smith J; Haworth SG
    Arch Dis Child Fetal Neonatal Ed; 2005 Nov; 90(6):F527-8. PubMed ID: 16244212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase type 5 and high altitude pulmonary hypertension.
    Aldashev AA; Kojonazarov BK; Amatov TA; Sooronbaev TM; Mirrakhimov MM; Morrell NW; Wharton J; Wilkins MR
    Thorax; 2005 Aug; 60(8):683-7. PubMed ID: 16061711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
    Zhao L; Mason NA; Strange JW; Walker H; Wilkins MR
    Circulation; 2003 Jan; 107(2):234-7. PubMed ID: 12538421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.